knowledge -WSS

knowledge

author：knowledge 2025-09-29 19:06:12 - browse：57

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The UK government moves asylum

WSS

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

PBM reforms clear House panel

CRISPR pioneers react to Casgevy, first gene

Does good food count as health care? Study aims to find out

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Drug repurposing or repositioning? The language matters

Ransomware attacks on hospitals: Study outlines patient impact

BioMarin wins approval for gene therapy to treat hemophilia A

Why medical students are struggling with mental health

Tori Bowie and the unacceptable rates of Black maternal death

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

The cancer drug shortage isn’t new — and neither are the solutions

Anthos stroke drug appears safer than common blood thinner

23andMe had bad news about my health. I wish a person had delivered it

Boeing's 1st astronaut flight bumped into next year, more repairs needed

knowledge

'The Exorcist' director William Friedkin dead at 87

Trump Jan. 6 attorney John Lauro is ex

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Congress must reauthorize a committee to support older Americans

Moderna hits safety problems in bold bid to reinvent medicine

Wikipedia

hotspot

Wikipedia

focus